Evaluation of the efficacy of Ekal Dravya Jyotishmati (Celastrus paniculatus) in the management of Generalized Anxiety Disorder (Chittodvega) - A single-arm study

Abstract

Background- Generalized Anxiety Disorder (GAD) is a mental disorder characterized by an anxious state of mind that presents with symptoms like restlessness, irritability, sleep disturbances, tension, palpitations, dry mouth, and sweating. It predominantly affects women, especially in midlife, with a prevalence of 10% among women over 35. In modern treatment, selective serotonin reuptake inhibitors (SSRIs) such as sertraline are commonly prescribed as first-line therapy. GAD is referred to as Chittodvega in Ayurveda. Jyotishmati (Celastrus paniculatus), is mentioned as a Medhya drug in the Ayurvedic texts that enhances cognitive function and emotional well-being potentially offering benefits for managing GAD.

Aim and Objectives- To evaluate the efficacy of Jyotishmati in the management of GAD (Chittodvega).

Materials and Method-

In this trial, a total of 35 patients were enrolled for the study. Patients between 20–50 years of age of either gender having symptoms of GAD (Chittodvega) and a Hamilton anxiety rating (HAM-A) scale score less than 24 (i.e., mild to moderate) were selected for the study. In the trial intervention, Jyotishmati Capsules 500 mg were given twice a day after food with water for 60 days.

Observations and Result- Data of 35 patients were used for statistical analysis and significant improvements were noticed in the HAM-A Score, Serum cortisol levels and the WHOQOL Score from baseline to the subsequent follow-ups on the 30^th, 60^th, and 90^th day.

Conclusion- Jyotishmati Capsule is effective in significantly reducing anxiety symptoms, HAM-A Score, and Serum Cortisol levels and improves the quality of life of patients.